CN Patent

CN110693822A — 一种布洛芬注射液及制备方法

Assigned to Shandong Luoxin Pharmaceutical Group Hengxin Pharmacy Co Ltd · Expires 2020-01-17 · 6y expired

What this patent protects

本发明涉及布洛芬注射液，该注射液的处方包括：主药布洛芬和助溶剂精氨酸，精氨酸在处方中用量为83.75mg/ml‑95mg/ml，且精氨酸与布洛芬摩尔比为0.99:1‑1.18:1，注射液的pH值范围为7.8‑8.8。本发明所制得产品质量优于现有技术，稳定性及安全性良好。

USPTO Abstract

本发明涉及布洛芬注射液，该注射液的处方包括：主药布洛芬和助溶剂精氨酸，精氨酸在处方中用量为83.75mg/ml‑95mg/ml，且精氨酸与布洛芬摩尔比为0.99:1‑1.18:1，注射液的pH值范围为7.8‑8.8。本发明所制得产品质量优于现有技术，稳定性及安全性良好。

Drugs covered by this patent

Advil (ibuprofen) · Generic (originally Boots Group)

Patent Metadata

Patent number: CN110693822A
Jurisdiction: CN
Classification: —
Expires: 2020-01-17
Drug substance claim: No
Drug product claim: No
Assignee: Shandong Luoxin Pharmaceutical Group Hengxin Pharmacy Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.